Home
| Log in or Sign Up for full access
| Tracked Organizations
| Recent Tracked Activities
Recent Activities
Activities between Nov. 15, 2024, 7:48 p.m. and Nov. 22, 2024, 7:48 p.m.
from: Veterinary Industry.
Click on a document link to see the original source document.
Click on the name of an organization to see more organization linkages and timelines.
Document Date: Nov. 21, 2024, 1 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership:
Document Extract: Pieper Veterinary Partners with Norwichtown Veterinary Hospital in Norwich, CT. MIDDLETOWN, Conn., Nov. 21, 2024 /PRNewswire/ - Pieper Veterinary, a leading network of primary, specialty, and emergency veterinary hospitals in the Northeast, is thrilled to announce its new partnership with Norwichtown Veterinary Hospital-a respected practice known for its excellence in both small and large animal care. This collaboration brings together two outstanding teams, enhancing service offerings, resource sharing, and a mutual dedication to exceptional veterinary care throughout Connecticut. Norwichtown Veterinary Hospital, purchased by Dr. Geoffrey Satterfield in August 2016, has grown from a small animal and exotic practice into a comprehensive mixed-animal practice, providing care for both small and large animals, including after-hours emergency services for the community. Dr. Satterfield, a U.S. Marine veteran, has built the hospital on a foundation of compassionate and accessible care, while earning a trusted reputation and supporting its continued growth.
Document Source: https://www.prnewswire.com/news-releases/pieper-veterinary-partners-with-norwichtown-veterinary-hospital-in-norwich-ct-302312553.html
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 1 p.m. / Source: prweb
Activity Class: PartnershipActivity
Partnership:
Document Extract: The strategic partnership between Purdue and Akston was announced in August after the underlying technology was developed at the College of Veterinary Medicine and the Purdue Institute for Cancer Research (PICR) . Invasive urothelial carcinoma (InvUC) , also known as transitional cell carcinoma (TCC) , is the most common and aggressive type of urinary bladder cancer in dogs. While it often starts in the bladder, it can also develop in other parts of the urinary tract and can spread to the lymph nodes, lung, liver and other organs. Although the treatment of InvUC has improved over several years, and the quality of life while living with the cancer can be quite good, the cancer is rarely curable. Over time, the cancer typically develops resistance to treatment and progresses.
Document Source: https://www.prweb.com/releases/purdue-university-and-akston-biosciences-bring-first-dose-of-hope-in-new-cancer-immunotherapy-trial-for-dogs-with-urinary-bladder-cancer-302309488.html
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 1 p.m. / Source: prweb
Activity Class: PartnershipActivity
Partnership:
Document Extract: Purdue University and Akston Biosciences Bring "First Dose of Hope" in New Cancer Immunotherapy Trial for Dogs with Urinary Bladder Cancer. Study enrolls dogs with urothelial carcinoma to assess anti-cPD-L1 monoclonal antibody (mAb) safety and efficacy, with potential applications for human treatments. BEVERLY, Mass. and WEST LAFAYETTE, Ind., Nov. 19, 2024 /PRNewswire-PRWeb/ - Purdue University and its College of Veterinary Medicine, in partnership with Akston Biosciences Corporation, has initiated the enrollment of dogs with urinary bladder cancer in a clinical trial of a pioneering immunotherapy. The immunotherapy consisting of an anti-cPD-L1 monoclonal antibody (mAb) is designed to target and block the cPD-L1 protein on cancer cells.
Document Source: https://www.prweb.com/releases/purdue-university-and-akston-biosciences-bring-first-dose-of-hope-in-new-cancer-immunotherapy-trial-for-dogs-with-urinary-bladder-cancer-302309488.html
(archive.org page /
archive.org listing)
Document Date: Nov. 18, 2024, 2:30 p.m. / Source: PR Newswire
Activity Class: CorporateFinanceActivity
/ Type: Investment
Investor:
- L Catterton
/ Industry: Consumer Services, Fashion And Apparel and 5 more
Target:
- WeVets
/ Industry: Veterinary Industry
Document Extract: L Catterton Latin America Makes Strategic Investment in WeVets.
Document Source: https://www.prnewswire.com/news-releases/l-catterton-latin-america-makes-strategic-investment-in-wevets-302308545.html
(archive.org page /
archive.org listing)
Document Date: Nov. 20, 2024, 11:30 a.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity
/ Type: Acquisition
/ Region: United States
Buyer:
- Henry Schein
/ Industry: Animal Health Diagnostics, Dental Services and 5 more
Target:
- Acentus
/ Industry: Hospital Management Service
Document Extract: Henry Schein, Inc. (Nasdaq: HSIC) , the world's largest provider of health care solutions to office - based dental and medical practitioners, announced today that it has signed an agreement to acquire Acentus, a national medical supplier specializing in the delivery of Continuous Glucose Monitors (CGMs).
Document Source: https://www.businesswire.com/news/home/20241119215268/en/Henry-Schein-to-Acquire-Acentus-a-Leading-Supplier-of-Homecare-Medical-Products
(archive.org page /
archive.org listing)
Document Date: Nov. 20, 2024, 11:30 a.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity
/ Type: Acquisition
Buyer:
- Henry Schein
/ Industry: Animal Health Diagnostics, Dental Services and 5 more
Target:
Document Extract: The Acentus transaction follows Henry Schein's acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and Mini Pharmacy in 2023, reinforcing the Company's strategic commitment to the homecare medical supplies market.
Document Source: https://www.businesswire.com/news/home/20241119215268/en/Henry-Schein-to-Acquire-Acentus-a-Leading-Supplier-of-Homecare-Medical-Products
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 2 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership:
Document Extract: " We are thrilled to team with Lahey Hospital & Medical Center to improve the health of the communities it serves by improving lung cancer screening rates while expanding our reach to the Northeast. Today, screening rates are paltry - under 10 % nationwide ," said Peter B. Bach, DELFI's Chief Medical Officer. " FirstLook Lung offers providers and their patients an accessible and convenient way to improve lung cancer detection through a simple blood test ." FirstLook Lung evaluates patterns of DNA fragments in the blood that reveal the presence of lung cancer. In an independent validation, FirstLook Lung was shown to have very high sensitivity in a screening population, including detecting the earliest stages of the disease.
Document Source: https://www.prnewswire.com/news-releases/delfi-diagnostics-selects-lahey-hospital--medical-center-to-administer-new-lung-cancer-screening-test-302301611.html
(archive.org page /
archive.org listing)
Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.
Treat sameAsNameOnly relationship as same? Yes
(Turn Off)
Site Stats
| About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License.
Please send an email if you need a non-share-alike license and/or you need API access.